



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **Pratt**

Application No: **10/824,593**

Group Art Unit: **1615**

Filed: **April 15, 2004**

Examiner: **Channavajjala**

For: **Methods for Treating Substance Abuse with Cholinesterase Inhibitors**

Docket: **222919**

Commissioner of Patents  
PO Box 1450  
Alexandria, VA 22313-1450


### INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicant brings to the attention of the Examiner the documents listed on the attached PTO-1449 Form. A copy of the cited documents is submitted herewith.

The submission of this Information Disclosure Statement does not represent that a search has been made and does not constitute an admission that the listed documents are prior art or material to patentability.

This Information Disclosure Statement is being filed after the mailing date of a first office action on the merits but before a final office action or a notice of allowance. The Commissioner is authorized to charge the fee of \$180 to Deposit Account No. 22-0261.

Applicant respectfully requests that an initialed copy of the PTO-1449 Form be returned with the next communication from the Office.

Respectfully submitted,  
  
Edward D. Grieff  
Registration No. 38,898

Date: July 10, 2006

VENABLE LLP  
575 7th Street, NW  
Washington, DC 20004  
Phone: 202-344-4382



JUL 10 2006

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**Complete if Known**

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	5	Attorney Docket Number	222919
-------	---	----	---	------------------------	--------

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Kato et al, Neurosci. Lett., 260(1):5-8 (1999).	
		Hikida et al, PNAS, 100(10):6169-6173 (May 13, 2003).	
		Jovanovski et al, Hum. Psychopharmacol., 18(7):561-564 (October 2003).	
		Kim et al, Pharmacotherapy, 24(3):419-421 (March 2004).	
		Casadevall-Codina et al, Rev Neurol, 35(4):341-345 (2002).	
		Sahin et al, Clinical Neuropharmacology, 25(1):16-20 (2002).	
		Iga et al, Alcohol & Alcoholism, 36(6):553-555 (2001).	
		Angunawela et al, Int. J. Geriatr Psychiatry, 16:338-339 (2001).	
		Wengel et al, Journal of Geriatric Psychiatry and Neurology, 11:159-161 (1998).	
		Cochrane et al, Alcohol & Alcoholism, pages 1-4 (2004).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

5

<i>Complete if Known</i>	
Application Number	10/824,593
Filing Date	April 15, 2004
First Named Inventor	Pratt
Art Unit	1615
Examiner Name	Channavajjala
Attorney Docket Number	222919

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Ridder et al, Ned Tijdschr Geneeskd, 149(30):1701-1703 (2005) (Abstract).	
		Cochrane et al, Alcohol Alcohol., 40(2):151-154 (2005) (Abstract).	
		Jovanovski et al, Hum Psychopharmacol, 18(7):561-564 (2003) (Abstract).	
		Gibson et al, West Indian Med J, 52(1):59-61 (2003) (Abstract).	
		Rodriguez-Perez et al, Vet Hum Toxicol, 45(3):146-147 (2003) (Abstract).	
		Zhou et al, Biomed Environ Sci, 16(1):53-61 (2003) (Abstract).	
		Hikida et al, PNAS USA, 100(10):6169-6173 (2003) (Abstract).	
		Casadevall-Codina et al, Rev Neurol, 35(4):341-345 (2002) (Abstract).	
		Sahin et al, Clin Neuropharmacol, 25(1):16-20 (2002) (Abstract).	
		Iga et al, Alcohol Alcohol., 36(6):553-555 (2001) (Abstract).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**Complete if Known****INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT***(Use as many sheets as necessary)*

Sheet

3

of

5

Application Number

10/824,593

Filing Date

April 15, 2004

First Named Inventor

Pratt

Art Unit

1615

Examiner Name

Channavajjala

Attorney Docket Number

222919

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Gann et al, Sleep Res Online., 1(2):92-95 (1998) (Abstract).	
		Valmaggia et al, Strabismus, 9(1):9-12 (2001) (Abstract).	
		Buccafusco et al, Brain Res, 852(1):76-83 (2000) (Abstract).	
		Wengel et al, J. Geriatr Psychiatry Neurol., 11(3):159-161 (1998) (Abstract).	
		Spencer et al, Drugs Aging., 13(5):391-411 (1998) (Abstract).	
		Amlo et al, Tidsskr Nor Laegeforen, 117(18):2610-2612 (1997) (Abstract).	
		Sharif et al, Neurosci Res., 25(2):155-160 (1996) (Abstract).	
		Avakian et al, Zh Nevropatol Psichiatr Im S S Korsakova, 90(3):44-49 (1990) (Abstract).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**Complete if Known****INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT***(Use as many sheets as necessary)*Sheet **4** of **5**Application Number **10/824,593**Filing Date **April 15, 2004**First Named Inventor **Pratt**Art Unit **1615**Examiner Name **Channavajjala**Attorney Docket Number **222919****NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Walker et al, JACEP, 5(6):436-439 (1976) (Abstract).	
		Kloszewska, Psychiatr Pol, 36(6 Suppl):133-141 (2002) (Abstract).	
		Winhusen et al, Addiction, 100(Suppl 1):68-77 (2005) (Abstract).	
		Hori et al, Psychiatry Clin Neurosci, 57(6):603-604 (2003) (Abstract).	
		Phillips et al, Psychosomatics, 45(4):366-368 (2004) (Abstract).	
		Gann et al, Biol Psychiatry, 50(5):383-390 (2001) (Abstract).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 5 of 5 Attorney Docket Number 222919

**Complete if Known**

Application Number	10/824,593
Filing Date	April 15, 2004
First Named Inventor	Pratt
Art Unit	1615
Examiner Name	Channavajjala

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Gorelick, Grant No. 1Z01DA000240-12, two pages, 2004 (Abstract).	
		Hunt, Grant No. 1R01AA015343-01, two pages, 2005 (Abstract).	
		Newton, Grant No. 1P50DA018185-010001, two pages, 2004 (Abstract).	
		Shopta, Grant No. 1P50DA018185-010002, two pages, 2004 (Abstract).	
		Woods, Grant No. 1R01DA014023-01, two pages, 2001 (Abstract).	
		Woods, Grant No. 5R01DA014023-02, two pages, 2001 (Abstract).	
		Hill et al, Neurology, 58:62-70 (2002) (Abstract).	
		Fillit et al, "Alzheimer's disease increases healthcare utilization and costs in patients with common medical comorbidities," Institute for the Study of Aging.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:  
**Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.